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Introduction {#sec1}
============

The internal membrane systems of the eukaryotic cell are highly dynamic, and their regulated remodeling is essential for proper organelle function, during both normal cell growth and stress. For example, the nuclear membrane undergoes dynamic remodelling during the two modes of nuclear division operating in eukaryotes, "open" and "closed" mitosis ([@bib70], [@bib60]), and the accumulation of unfolded proteins in the endoplasmic reticulum (ER) drives significant ER membrane expansion in order to support increased protein folding capacity ([@bib63]). Therefore, cells must possess mechanisms to selectively add, remove, or remodel membrane phospholipids at different organelles in response to cell cycle and stress signals, but those remain poorly understood.

Lipid precursors, which are normally directed toward membrane synthesis to promote cell growth, are diverted toward storage during nutrient limitation. The main metabolic energy storage molecules in eukaryotes are triacylglycerols (TGs) which, together with other neutral lipids (e.g., steryl esters), are deposited in lipid droplets (LDs) ([@bib64]). LDs emerge from, and remain associated with, the ER membrane in many cell types and interact with other organelles ([@bib3]). Some of these interactions involve LDs with their "client" organelles, such as mitochondria and peroxisomes, which catabolize fatty acids stored in TGs and provide an essential source of energy during starvation ([@bib20], [@bib48]). Other interactions suggest a link of LDs to organelle membrane biogenesis. For example, LDs have been proposed to provide lipid precursors for autophagosome membrane biogenesis in yeast and mammals ([@bib10], [@bib55]). Similarly, a specific pool of LDs associate with the expanding prospore membrane that sequesters the meiotic nuclei during sporulation of yeast cells ([@bib49], [@bib21]), and LD-mobilized fatty acids are required for bud growth and cell cycle progression in yeast ([@bib30]).

TG is synthesized by acyl-CoA:diacylglycerol acyltransferases (DGATs) or phospholipid-diacylglycerol acyltransferases (PDATs) ([@bib53]). Most eukaryotes express DGATs while PDATs have been described so far in fungi, microalgae, and plants. Whereas DGATs use a fatty acid activated with coenzyme A (FA-CoA) to acylate diacylglycerol (DG), PDATs transfer a fatty acid from a phospholipid directly to DG ([Figure 1](#fig1){ref-type="fig"}A). Accordingly, PDATs couple TG synthesis to membrane phospholipid deacylation ([@bib9], [@bib41]) ([Figure 1](#fig1){ref-type="fig"}B).Figure 1Lro1 Targets a Nuclear Membrane Subdomain that Associates with the Nucleolus(A) Schematic of the major lipid metabolic pathways in yeast; PA, phosphatidate; DG, diacylglycerol; TG, triacylglycerol; FA, fatty acid: LPL, lysophospholipid.(B) Schematic of the PDAT activity; PL, phospholipid.(C) Localization of Lro1-GFP expressed under the control of its own promoter in cells co-expressing an ER (Sec63-mCherry) reporter at the indicated growth phases.(D) Schematic of the organization of the yeast nucleus.(E) Co-localization of Lro1-GFP as in C but with a nucleolar reporter.(F) Left panels: examples of nucleolar enrichment of Lro1-GFP during the exponential phase; right panel, quantification from three experiments, n = 343 cells.(G) Quantification of Lro1 targeting to the nucleolar-associated membrane in response to various stresses. Exponentially growing cells expressing a chromosomally integrated nucleolar reporter (*NOP10*-mCherry) were subjected to the indicated stresses and the percentage of Lro1-GFP targeting to the nucleolar-associated membrane was quantified (n = 3 experiments, at least 600 cells counted per stress condition); comparisons are between 1 or 2 h and PDS.(H) Immunolabeling of chemically fixed yeast cells expressing Lro1-6xHA. Arrowheads point to gold particles clustering on one side of the nuclear envelope. Stars indicate LDs. MVB, multivesicular bodies; M, mitochondria. Scale bars in (C), (E), and (F), 5 μm; in H, 500 nm. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; ns, not significant.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Here, we uncover a phospholipid remodeling pathway that targets a specific subdomain of the inner nuclear membrane (INM). We find that the PDAT Lro1 of *Saccharomyces cerevisiae* (from hereon called yeast) is imported from the ER to the INM abutting the nucleolus. Lro1 is active at this specific nuclear subdomain resulting in the utilization of phospholipid-derived fatty acids to generate TGs and lysophospholipids. Interestingly, targeting of Lro1 is regulated by cell cycle and nutrient signals and is inhibited when the nucleus expands. Notably, we find that synthesis of TG at the INM sustains survival during starvation, suggesting the presence of a pathway that exports TG to the cytoplasmic side of the ER.

Results {#sec2}
=======

Cell Cycle and Nutrient Signals Cause Dynamic Targeting of Lro1 to a Nuclear Membrane Subdomain Associated with the Nucleolus {#sec2.1}
-----------------------------------------------------------------------------------------------------------------------------

To determine if PDATs have a role in specific membrane remodeling events during nutrient depletion, we examined the subcellular localization of a C-terminally GFP-tagged Lro1 fusion protein when nutrients start to become scarce. All Lro1 fusions used for localization studies were catalytically active ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Lro1-GFP localizes to the ER during the exponential growth phase (EXP), when lipid intermediates are used to drive phospholipid synthesis to sustain rapid growth, but it relocates to a subdomain of the nuclear envelope as cells face nutrient depletion during diauxic shift (post-diauxic shift \[PDS\] phase; [Figure 1](#fig1){ref-type="fig"}C; [@bib71]). This was observed when plasmid-borne Lro1-GFP was expressed from its own promoter or from the stronger *NOP1* promoter ([Figures 1](#fig1){ref-type="fig"}C and [S1](#mmc1){ref-type="supplementary-material"}B) as well as when Lro1-GFP was integrated at its chromosomal locus ([Figure S1](#mmc1){ref-type="supplementary-material"}C). The morphology of the Lro1-GFP membrane domain is reminiscent of the nucleolus, which adopts a crescent-like shape and is tethered to the INM in yeast ([@bib58]) ([Figure 1](#fig1){ref-type="fig"}D). Using the nucleolar reporter Nop1-RFP, we demonstrated that Lro1-GFP indeed accumulates at the membrane bordering the nucleolus ([Figure 1](#fig1){ref-type="fig"}E). Interestingly, careful analysis of Lro1 localization during exponential phase also revealed, in addition to its ER localization, an enrichment of Lro1 at the subdomain bordering the nucleolus in 34.0% ± 5.6% unbudded and 34.5% ± 2.7% small budded cells, but only in 3.8% ± 5.0% of large budded cells ([Figure 1](#fig1){ref-type="fig"}F). This is consistent with Lro1-GFP accumulation at the nucleolus in PDS phase since yeast cells arrest at the G1 phase of the cell cycle at the diauxic shift ([@bib36]). We also observed a similar accumulation of Lro1-GFP at this subdomain during acute glucose starvation, during growth in non-fermentable carbon sources, or when transferring the cells in water but not upon nitrogen deprivation ([Figure 1](#fig1){ref-type="fig"}G) or inhibition of rDNA transcription ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Immunoelectron microscopy revealed that an Lro1-6xHA fusion preferentially associated with the perinuclear ER during exponential phase (i.e., 62.6% ± 0.36%), and only part of it was at the cortical and/or peripheral ER (37.3% ± 0.21%), respectively. In the PDS phase, a significant decrease in Lro1 protein levels (see later) reduced the labeling efficiency, precluding statistical quantifications. Nevertheless, in the few cell sections where Lro1-6xHA was detected, this fusion protein was mostly found on one side of the nuclear envelope and always adjacent to LDs ([Figure 1](#fig1){ref-type="fig"}H). Taken together, these results show that glucose limitation and cell cycle signals target Lro1 to a subdomain of the nuclear membrane, which is in contact with the nucleolus.

Lro1 Is Targeted to the INM {#sec2.2}
---------------------------

Lro1 is a type II integral membrane protein with a short basic cytosolic N-terminal domain and a larger luminal catalytic domain ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A; [@bib7]). Expression of its N-domain fused to GFP shows a clear intranuclear localization with enrichment at the nucleolus ([Figures 2](#fig2){ref-type="fig"}B, panel 2 and [S2](#mmc1){ref-type="supplementary-material"}B). Notably, the N-domain with the transmembrane segment also accumulates at the membrane in contact with the nucleolus ([Figure 2](#fig2){ref-type="fig"}B, panel 4 versus 6). Mutating the K/R residues within two basic clusters into alanines abrogates the nucleolar enrichment of both fusions in PDS phase ([Figure 2](#fig2){ref-type="fig"}B, panel 2 versus 3; panel 4 versus 5). Unexpectedly, the same mutations only partially compromise the targeting of Lro1 within the context of the full-length protein, indicating the presence of additional targeting determinants ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). To examine whether these also map in the N-domain, we replaced it with 4 IgG binding domains of Protein A (4xIgGb) and found that this prevented detection of the resulting GFP fusion at the PDS phase, both at the nucleolus and at the ER. Because the stability of Lro1 is controlled by the ubiquitin-protein ligase Hrd1 ([@bib23]), we imaged 4xIgGb-Lro1-GFP in an *hrd1*Δ strain and found out that it could be detected at the ER but not at the nucleolar-associated membrane, at the PDS phase ([Figures 2](#fig2){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}C). Together, these results show that the N-domain of Lro1 is necessary and sufficient for its efficient targeting to the nuclear membrane subdomain in contact with the nucleolus; when this targeting fails in PDS, Lro1 is unstable in the ER.Figure 2Translocation of Lro1 to the INM that Associates with the Nucleolus(A) Schematic of the topology of Lro1. The K/R-rich nucleolar targeting sequences are shown in red. The Ser324 within the GHSXG lipase motif is shown.(B) *lro1*Δ cells expressing a nucleolar reporter and the Lro1-GFP mutants shown were imaged at the indicated growth phases. Red stars denote the K/R to A mutations. Arrowheads denote the nucleolus and/or the nucleolar-associated membrane.(C) Quantification of the subcellular localization of the indicated Lro1-GFP mutants in the specified strains. Red stars denote the K/R to A mutations within the extralumenal domain. Three colonies of each strain were analyzed; at least 200 cells were counted for each strain.(D) Lro1-GFP was photobleached, either at the nucleolar-associated membrane or the cortical ER (cER), and fluorescence recovery was measured. Data are means ± SD from three independent experiments (seven cells each); arrow indicates the bleaching event.(E) Nucleolar-associated membrane targeting of 1x-, 2x-, or 3x-MBP-Lro1-GFP fusions during the PDS phase. Right panel: Quantification of the data shown from three experiments, counting only cells with signal in ER or nucleolus; at least 250 cells were quantified for each strain.(F) Localization of the FRB-GFP control (the outlines of cells are shown; vac, vacuole), and the FRB-Lro1-GFP (middle) or FRB-3xMBP-Lro1-GFP (bottom) fusions, before or after the addition of rapamycin. Arrowheads point to the cortical ER membrane. Scale bars in all micrographs, 5 μm. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Next, we compared the dynamics of the two pools of Lro1 using fluorescence recovery after photobleaching (FRAP). We found that these exhibit different properties: the nucleolar-associated membrane pool of Lro1-GFP was more immobile and its fluorescence recovery was significantly slower than that of the cortical ER, suggesting the presence of a limiting step in its targeting ([Figures 2](#fig2){ref-type="fig"}D, [S2](#mmc1){ref-type="supplementary-material"}D, and S2E). Given that its soluble N-domain associates to the nucleolus, we asked whether Lro1 accesses the inner side of the nuclear membrane. We applied two assays to address this question: the first approach was based on the fact that import of integral membrane proteins from the ER to the INM through the nuclear pore is limited by the size of their cytosolic domains, with the cutoff in yeast being 90 kDa ([@bib47]). In support of Lro1 residing in the INM, Lro1-GFP nucleolar targeting was significantly compromised when its extralumenal domain was made larger by appending 1, 2, or 3 copies of the maltose-binding protein (MBP) ([Figures 2](#fig2){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}F). Moreover, we found that increasing the size of the N-terminal domain of Lro1 and/or preventing its nuclear import results in a significant decrease in its protein levels ([Figure S2](#mmc1){ref-type="supplementary-material"}G), explaining why many cells have low 3xMBP-Lro1-GFP signal at the ER in the PDS phase. To independently determine whether Lro1 can associate with the INM, we used a second assay based on the anchor-away technique ([@bib19]). This approach requires the co-expression of two chimeric proteins: firstly, the INM protein Heh1 was fused to the FK506 binding protein (FKBP12); secondly, Lro1-GFP, or GFP as control, was fused to the FKBP12-rapamycin-binding (FRB) domain ([Figure S2](#mmc1){ref-type="supplementary-material"}H). FRB and FKBP12 form a high-affinity ternary complex in the presence of rapamycin if they are in close proximity. Following the addition of rapamycin, FRB-GFP changed rapidly (30 min) from a diffuse to a ring-like localization, confirming that the INM anchor is indeed accessible to FRB-GFP ([Figure 2](#fig2){ref-type="fig"}F). Addition of rapamycin in the strain expressing FRB-Lro1-GFP resulted in the loss of its cortical ER localization and its accumulation at a perinuclear ring, which is typical of INM proteins. In contrast, FRB-3xMBP-Lro1-GFP retained its cortical ER localization after rapamycin treatment ([Figure 2](#fig2){ref-type="fig"}F), consistent with an impairment in nucleolar targeting when the mass of the N-terminal domain increases. Taken together, these data show that Lro1 targets the INM by virtue of its N-domain.

Lro1 Is Catalytically Active at the INM in Contact with the Nucleolus {#sec2.3}
---------------------------------------------------------------------

The nuclear membrane associated with the nucleolus has the property of being particularly susceptible to expansion in response to excess phospholipid synthesis ([@bib5], [@bib27], [@bib67]). We therefore examined whether Lro1 is active by following TG synthesis at this membrane subdomain. To do this, we first sought to express Lro1 in a background where it would be the sole source of neutral lipid; hence, we used a mutant with deletions in the two DG acyltransferases (*LRO1* and *DGA1*) and the two steryl acyltransferases (*ARE1* and *ARE2*), henceforth called 4Δ, and which lacks neutral lipids and LDs ([@bib40], [@bib46]). Given that synthesis of neutral lipids is essential for cell survival in stationary phase, 4Δ cells display accelerated cell death in PDS that can be rescued by the expression of Lro1 as the only source of TG. This rescue requires the catalytic activity of Lro1 because mutation of Ser324 within its conserved GHSXG lipase motif abolishes the appearance of LDs (data not shown) and survival in PDS ([Figure 3](#fig3){ref-type="fig"}A). Importantly, TG levels rise concomitantly with increases in the levels of Lro1-GFP at the nucleolar-associated membrane in 4Δ cells in time course experiments during exit from exponential growth ([Figures 3](#fig3){ref-type="fig"}B and 3C). Three-dimensional reconstruction of the LD distribution relative to Lro1-mCherry in 4Δ cells shows that in 86% (±2.5%, n = 3 experiments) of the cells at least one LD is in close proximity with the Lro1-mCherry punctum in the PDS phase ([Figure 3](#fig3){ref-type="fig"}D; [Video S1](#mmc4){ref-type="supplementary-material"}). LDs in the vicinity of the nucleolus were also observed during live imaging of 4Δ cells expressing Lro1 ([Video S2](#mmc5){ref-type="supplementary-material"}). In both experiments, LDs that are not in proximity to the nucleolus can still be detected; these may be derived from Lro1 activity at the ER during the exponential phase or their mobility within the perinuclear ER. Taken together, these results support the notion of Lro1 being active at the INM.Figure 3Lro1 Is Catalytically Active at the Nucleolar-Associated INM(A) Wild-type or *dga1*Δ *lro1*Δ *are1*Δ *are2*Δ (4Δ) cells expressing the indicated plasmids were grown to exponential (EXP) or PDS phases in minimal synthetic medium and spotted on YEPD plates.(B) 4Δ cells expressing Lro1-GFP and Sec63-mCherry were grown from exponential phase to the indicated densities and imaged.(C) 4Δ cells expressing Lro1, or an empty vector, were grown to the indicated densities, labeled with BODIPY 493/503 and their fluorescence was quantified by FACS. Data are representative of two independent experiments.(D) 4Δ cells expressing Lro1-mCherry were grown to the PDS phase and labeled with BODIPY 493/503. Deconvolved through-focus image series were processed to generate 3D image. The full reconstructed field is shown in [Video S1](#mmc4){ref-type="supplementary-material"}.(E) Model for the Lro1-mediated regulation of phospholipid homeostasis; see text for details.(F) Co-localization of the indicated GFP fusions with Lro1-mCherry at the PDS phase.(G) Lipidomic quantifications of TG, LPE, LPC, PE, and PC in wild-type (BY4741), ale1Δ, and *plb1*Δ *plb2*Δ *plb3*Δ *nte1*Δ *lro1*Δ (5Δ) cells expressing the denoted plasmids. Cells were grown in galactose for 5 h. Lipid levels were normalized to the corresponding levels of the wild-type strain expressing the empty vector. Data shown are means of at least 5 experiments ± SD. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001. Scale bars in all micrographs, 5 μm. See also [Videos S1](#mmc4){ref-type="supplementary-material"} and [S2](#mmc5){ref-type="supplementary-material"}.

Video S1. Three-Dimensional Reconstruction of the LD Distribution Relative to Lro1 in PDS Phase

Video S2. Live Imaging of the Spatial Distribution of Lro1-Derived LDs Relative to the Nucleolus in PDS Phase

Lro1 Activity Regulates Phospholipid Homeostasis {#sec2.4}
------------------------------------------------

Next, we investigated the effect of Lro1 activity on membrane phospholipid homeostasis. We hypothesized two scenarios: in the first, the lysophospholipid generated by Lro1 could be re-acylated with a different fatty acid, changing the physical properties of the membrane; in the second, the lysophospholipid could be further broken down by a phospholipase, effectively degrading the original phospholipid substrate of Lro1 ([Figure 3](#fig3){ref-type="fig"}E). To discriminate between these possibilities, we first determined the subcellular distribution of the known lysophospholipid acyltransferases (Ale1 and Slc1) or phospholipases B (Nte1 and Lpl1; Plb's 1 to 3 could not be visualized) when Lro1 localizes to the nucleolar-associated membrane. GFP-fusions of Ale1 and Nte1, and to a lesser degree Slc1, localized to the ER with no apparent co-enrichment with Lro1-mCherry during the PDS phase ([Figure 3](#fig3){ref-type="fig"}F). Next, we determined the consequences of Lro1 activity in lipid homeostasis: consistent with its PDAT activity, we found that transient overexpression of Lro1 in wild-type cells caused an increase in TG levels ([Figure 3](#fig3){ref-type="fig"}G). Cells lacking Ale1, which has general lysophospholipid acyltransferase activity in yeast ([@bib25], [@bib50], [@bib59]), showed an increase in both lyso-PC and lyso-PE levels compared with that seen in the wild-type strain under the same conditions; on the other hand, a mutant strain lacking four known phospholipases B showed no change in lyso-PC and a more modest increase in lyso-PE compared to that of the *ale1*Δ mutant ([Figure 3](#fig3){ref-type="fig"}G). This result is consistent with the Lro1-derived lysophospholipids being directed primarily to re-acylation. However, our data cannot exclude a role for additional enzymes in the processing of Lro1-derived lysophospholipids.

Lro1 Localization Correlates with Changes in Nuclear Morphology {#sec2.5}
---------------------------------------------------------------

Next, we sought to investigate the nuclear function of Lro1 by mutating proteins required for its INM targeting. To do this, we performed an unbiased screen for factors involved in Lro1 nucleolar targeting. We used high content automated microscopy, followed by manual inspection, to determine the localization of Lro1-GFP in 6,000 strains carrying the loss of function mutations in all yeast genes. We focused on mutants with defects in Lro1 targeting during the PDS phase (and hence displaying increased ER localization compared to the wild-type) or decreased overall Lro1-GFP signal due to the degradation of its ER pool in the PDS phase. We identified 137 such mutants, which affect diverse cellular functions ([Table S1](#mmc2){ref-type="supplementary-material"}). Nearly half of the genes of the ontology term "establishment of sister chromatid cohesion" affected Lro1-GFP targeting ([Table S1](#mmc2){ref-type="supplementary-material"}). These included components of the Ctf19 complex of the kinetochore, which display a G2/M delay, consistent with the finding that Lro1 localization is regulated during the cell cycle. In those mutants, Lro1-GFP showed increased ER localization mostly in large budded cells ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Effects of Lro1 on Nuclear Morphology(A) Lro1-GFP localization in BY4742 (wild-type), *ctf19*Δ, and *mcm21*Δ strains grown to the PDS phase.(B) The BY4741 strain expressing the indicated protein fusions was treated with α-factor; arrowheads point to the nuclear envelope "pocket" that encompasses the nucleolus.(C) BY4741cells expressing *PUS1-GFP*, *NOP1-RFP*, and an empty vector or a high-copy *GAL-LRO1* plasmid were transferred to galactose-containing medium to induce *LRO1* expression, incubated with nocodazole, and extended focal images were collected live. The percentage of arrested cells displaying the elongated nuclear membrane expansion containing the nucleolus (panel 2) was determined; panels 1 shows a typical nucleus without membrane expansion; data shown are means of 5 experiments (at least 360 cells per strain) ± SD.(D) *rad52*Δ cells expressing the indicated fluorescent fusion proteins and the denoted *LRO1* plasmids, were grown at the exponential phase and imaged as above; nuclear circularity of large budded cells was obtained from extended focal images cells as described in [STAR Methods](#sec5){ref-type="sec"}; right panels depict circularity measurements from round or expanded *rad52*Δ nuclei; arrowheads point to the nucleolar-associated membrane expansion; data shown are means of 6 experiments (at least 360 cells per strain) ± SD.(E) A strain carrying an INM anchor (see [Figure 2](#fig2){ref-type="fig"}) and expressing *PUS1-mCherry* and the indicated Lro1 fusions were incubated first with rapamycin, followed by nocodazole. Nuclear circularity was calculated as in D; data shown are means of 3 experiments (at least 260 cells per strain) ± SD. Scale bar for all micrographs, 5 μm. ^∗^p \< 0.05; ^∗∗∗^p \< 0.001. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

During G2/M mitotic delay, phospholipid synthesis is not halted resulting in expansion of the nuclear membrane that contains the nucleolus ([@bib67]). We asked whether other conditions that result in the expansion of this membrane domain correlate with loss of Lro1 targeting. During exposure to α-factor mating pheromone, a MAP kinase cascade induces the formation of an extended nuclear membrane "pocket" embracing the nucleolus ([@bib57]) ([Figure 4](#fig4){ref-type="fig"}B). Lro1-GFP is excluded from this subdomain in α-factor treated cells, while it was still detected in contact with the nucleolus in unperturbed cycling G1/S cells. Thus, under multiple conditions where the nucleus expands, cycling anaphase ([Figure 1](#fig1){ref-type="fig"}F), G2/M delayed ([Figure 4](#fig4){ref-type="fig"}A) or α-factor-treated cells ([Figure 4](#fig4){ref-type="fig"}B), Lro1-GFP is displaced from the nucleolar-associated membrane.

The exclusion of Lro1 from the expanding INM suggests that its presence could modulate nuclear morphology. To test this, we transiently overexpressed Lro1 under two conditions that promote nucleolar membrane expansion ([@bib67]). Firstly, galactose-driven expression of Lro1 led to a 2.6-fold decrease in the percentage of wild-type cells with expanded nuclei following G2/M arrest with nocodazole (from 79% ± 4% to 30% ± 5%, p \< 0.001) ([Figure 4](#fig4){ref-type="fig"}C). Secondly, we measured nuclear circularity in large budded *rad52*Δ, which display nucleolar expansion ([@bib67]), following galactose-induced Lro1 expression. Circularity ranges from 0 to 1, the latter corresponding to a perfect circle. *rad52*Δ nuclear circularity increased following Lro1 overexpression (from 0.78 ± 0.14 to 0.86 ± 0.12, p \< 0.001). Although Lro1-S324A overexpression also led to an increase in nuclear circularity in both conditions, the catalytic active enzyme was more efficient in restoring nuclear shape ([Figures 4](#fig4){ref-type="fig"}C and 4D). We next examined the role of Lro1 at the INM using the anchor-away technique in cells expressing the INM anchor Heh1-FKBP12 in combination with Lro1, FRB-Lro1, or FRB-Lro1-S324A. We first confirmed that FRB-Lro1 is catalytically active when anchored at the INM ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Next, we incubated the cells with rapamycin to anchor the FRB-Lro1 fusions to the INM and then induced nuclear expansion with nocodazole. Since our data show that Lro1 is controlled through both targeting and DG availability (see later), we deleted *DGK1* in this system to increase the DG levels at the INM. We find that FRB-Lro1 activity at the INM is required to increase nuclear circularity ([Figure 4](#fig4){ref-type="fig"}E). Collectively, these data show that Lro1 localization correlates with, and impacts, the membrane expansion of this nuclear subdomain.

Nuclear TG Synthesis Is Sufficient to Sustain Growth during Starvation {#sec2.6}
----------------------------------------------------------------------

Our data are consistent with a role for Lro1 in TG synthesis at the INM. However, since Lro1 partitions dynamically between cortical and perinuclear ER, it is possible that a pool of Lro1 remains active at the cortical ER at the PDS phase. Therefore, we asked whether redirecting Lro1 constitutively to the INM would be sufficient to support TG synthesis. We found that the INM-targeting sequence of Heh1 ([@bib34]) is sufficient to localize an Lro1 fusion (H1-Lro1-GFP) exclusively to a perinuclear ring both in wild-type or 4Δ cells, which is indicative of INM targeting ([Figures 5](#fig5){ref-type="fig"}A and 5B, panels 1 and 2). Consistently, disruption the Asi ubiquitin ligase complex, which mediates INM protein-specific degradation ([@bib13], [@bib28]), led to an increase in both the protein and the nuclear membrane fluorescence levels of H1-Lro1-GFP ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Two lines of evidence indicate that H1-Lro1 is active at generating TG at the INM in PDS phase: firstly, expression of H1-Lro1 in 4Δ led to a significant increase of TG levels ([Figure 5](#fig5){ref-type="fig"}C) and secondly, H1-Lro1 rescued the lethality of 4Δ in the PDS phase ([Figure 5](#fig5){ref-type="fig"}D). Strikingly, TG synthesis at the INM did not compromise long-term survival in stationary phase ([Figure 5](#fig5){ref-type="fig"}D).Figure 5INM Activity of Lro1 Supports TG Synthesis and Is Induced by Availability of Diacylglycerol(A) Schematic of the H1-Lro1 fusion. The Heh1 residues fused to Lro1 are shown; UP, unfolded peptide sequence.(B) Localization of the denoted Lro1-GFP fusions in 4Δ cells. Arrowheads point to the cortical ER membrane.(C) The 4Δ strain expressing either Lro1 or H1-Lro1, or an empty plasmid, was grown to the exponential or PDS phases. Lipids were extracted and TG quantified by mass spectrometry. TG levels shown are relative to internal TG standards of known concentration. Values shown are means from three independent cultures per strain.(D) Upper panel: growth of 4Δ cells in minimal synthetic medium expressing wild-type Lro1, or the indicated Lro1 mutants, in exponential phase or following recovery from the PDS phase. 5-fold dilutions were spotted onto YEPD plates. Lower panel: Survival of 4Δ cells expressing Lro1, or H1-Lro1, in minimal medium. Data are means ± SDs from three different cultures per strain.(E) Exponentially growing 4Δ cells expressing the indicated Lro1 constructs were stained with BODIPY 493/503 to label LDs.(F) 4Δ cells expressing H1-Lro1 and Nup84-mCherry were grown to the PDS phase, stained with BODIPY 493/503, and imaged live using Zeiss LSM880 confocal microscope equipped with an Airyscan unit, as described in [STAR Methods](#sec5){ref-type="sec"}, at 0.18 μm axial resolution, and 0.2 μm step slices with 50% overlap. The arrowhead points to a representative intranuclear LD. Arrows point to LDs that associate with the outer nuclear membrane.(G) 4Δ cells expressing H1-Lro1 were grown to the PDS phase and processed for electron microscopy as described in [STAR Methods](#sec5){ref-type="sec"}. CW, cell wall; M, mitochondria; N, nucleus; LD is marked with an asterisk.(H) 4Δ cells expressing H1-Lro1 were grown to the PDS phase and processed for high-pressure freezing and freeze substitution as described in [STAR Methods](#sec5){ref-type="sec"}. Scale bars in (B) and (E), 5 μm; in (F) and (G), 1 μm; in (H), 500 nm. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ns, not significant.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

We noticed, however, that 4Δ H1-Lro1 cells lack detectable LDs during exponential growth in standard glucose media ([Figure 5](#fig5){ref-type="fig"}E, panels 1 and 2). Cellular levels of DG, which is required for the formation of LDs, do not decrease significantly in the H1-Lro1 strain in the exponential phase ([Figure S3](#mmc1){ref-type="supplementary-material"}C). We therefore hypothesize that the INM is less accessible to DG than the cytosolic ER during the exponential phase. Two results support this hypothesis: (1) re-localization of H1-Lro1 to the ER, by removing a peptide from the Heh1 sequence, which is required for INM targeting of Heh1 ([@bib34]) ([Figure 5](#fig5){ref-type="fig"}B, panel 3) or (2) increasing DG levels at the nuclear membrane by overexpressing the active form of the PA phosphatase Pah1 or deleting the DG kinase *DGK1* increase TG levels and lead to the appearance of perinuclear LDs ([Figures 5](#fig5){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}D, panel 3). Collectively, these data are consistent with a model where the INM can support TG synthesis during the PDS phase, when DG concentrates at this subdomain of the ER.

Nuclear Lro1-Derived TG Is Packed into LDs Associated Mostly with the Outer Nuclear Membrane {#sec2.7}
--------------------------------------------------------------------------------------------

If TG, which is generated by Lro1 at the INM, can sustain cell viability during starvation, then this storage lipid has to become available to cytoplasmic organelles where its fatty acids are metabolized. To investigate this, we determined the spatial positioning of LDs with respect to the nuclear membrane in 4Δ H1-Lro1 cells during the PDS phase by using enhanced resolution Airyscan microscopy. As shown in [Figure 5](#fig5){ref-type="fig"}F, LDs were detected in the nucleoplasm in close proximity to the nuclear envelope in sequential z-slices that encompass the diameter of the LD. INM-associated LDs were also detected in 4Δ cells expressing wild-type Lro1 at the PDS phase ([Figure S3](#mmc1){ref-type="supplementary-material"}E). In both strains, however, LDs associated with the INM were rare. We found that the majority of LDs in the H1-Lro1 strain associate with the outer nuclear membrane. Electron microscopy using a cryo-sectioning procedure of chemically fixed cells for the morphological examination of 4Δ H1-Lro1 cells showed that LDs were associated with the outer side of the nuclear envelope but failed to resolve the nature of the LD-nuclear membrane association ([Figure 5](#fig5){ref-type="fig"}G). High-pressure freezing electron microscopy confirmed that LDs in this strain associate with the outer nuclear membrane ([Figure 5](#fig5){ref-type="fig"}H). Taken together, our data are consistent with a model where TG is exported from the INM and accumulates in the ONM, where it is packed into mature LDs.

Compartmentalization of INM TG Synthesis Is Important for Maintenance of Nuclear Integrity {#sec2.8}
------------------------------------------------------------------------------------------

Our data show that Lro1 can support TG synthesis when it localizes throughout the entire INM (H1-Lro1). In wild-type cells, however, Lro1 activity is restricted to a specific subdomain of the INM. We therefore wondered why yeast cells maintained this localized targeting of Lro1. We hypothesized that, when not confined, LD formation at the nuclear envelope may disrupt nuclear morphology and other nuclear functions, in particular under conditions of enhanced TG synthesis. To test this hypothesis, we first confirmed that the different localization of the Lro1 mutants correlates with a distinct subcellular distribution of LDs in 4Δ cells. Indeed, consistent with its constitutive perinuclear localization, H1-Lro1-derived LDs appeared nearly exclusively associated with the nuclear envelope in the PDS phase or after supplementation of oleate. In contrast, under the same conditions, cells expressing 3xMBP-Lro1 displayed an increased number of cortical LDs ([Figures 6](#fig6){ref-type="fig"}A and 6B). Next, we evaluated nuclear morphology in these cells by measuring the size and shape of their nuclei. The average cross-sectional surface of nuclei from the 4Δ H1-Lro1 cells (1.93 ± 0.78 μm^2^) showed a modest but significant decrease when compared with cells expressing the wild-type enzyme (2.08 ± 0.71 μm^2^), while the opposite result was observed for 4Δ 3xMBP-Lro1 cells (2.19 ± 0.84 μm^2^) ([Figure 6](#fig6){ref-type="fig"}C). To evaluate the nuclear shape, we measured nuclear circularity during the PDS phase. Circularity was significantly lower in 4Δ H1-Lro1 than in 4Δ Lro1 cells ([Figure 6](#fig6){ref-type="fig"}D). The nuclei of 4Δ 3xMBP-Lro1 cells displayed higher circularity than those of 4Δ H1-Lro1 cells although they displayed a modest decrease when compared to 4Δ Lro1 nuclei ([Figure 6](#fig6){ref-type="fig"}D). Thus, shifting Lro1 from the cortical ER to the INM decreases nuclear surface, consistent with a role of PDAT activity in organelle remodeling.Figure 6Compartmentalization of INM TG Synthesis Is Required to Maintain Nuclear Homeostasis(A) Distribution of LDs, labeled by BODIPY 493/503, in 4Δ cells expressing Nup84-mCherry and the indicated Lro1 proteins during the PDS phase; the cell outlines are shown. Scale bar, 5 μm.(B) Quantification of the association of LDs with the nuclear envelope in the strains shown in (A) (PDS phase; four experiments, n = at least 350 cells per strain) or in the same strains grown in exponential phase and incubated with glucose-containing media with 0.1% oleate for 2 h (three experiments, n = at least 400 cells per strain); data are means ± SDs.(C) Quantification of nuclear envelope surface area in 4Δ cells expressing the indicated Lro1 proteins at the PDS phase; data are means from five experiments (n = at least 400 per strain counted) ± SDs.(D) Quantification of nuclear envelope circularity in the samples from (A); data are means from six experiments and at least 400 cells per strain.(E) Loss of *VPS4* inhibits growth of 4Δ H1-Lro1 cells in the presence of oleate. The indicated strains expressing the Lro1 constructs shown were grown to the exponential phase in glucose-containing medium, spotted on YEPD plates in the absence or presence of 1 mM oleate and grown for 2 days.(F) Loss of *CHM7* inhibits growth of 4Δ H1-Lro1 cells in the presence of oleate. The specified strains were grown as described above.(G) Loss of *NUP188*, but not *POM152*, inhibits growth of 4Δ H1-Lro1 cells in the presence of oleate. The specified strains were grown as described above.(H) Model for the export of Lro1-derived TG to the outer nuclear membrane; see discussion for details. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.

Next, we asked whether constitutive LD formation at the INM compromises nuclear homeostasis. Maintenance of nuclear envelope integrity and repair is mediated by the ESCRT-III machinery ([@bib65], [@bib44], [@bib62]). We therefore examined whether ESCRT-III would be required for cell viability when the only source of TG synthesis, during fatty acid overload, would be at the INM. To test this, we deleted *VPS4*, a key component of ESCRT-III, in 4Δ H1-Lro1 and challenged the cells with oleate. While the single mutants of either *vps4*Δ or 4Δ H1-Lro1 grew in the presence of oleate, the double mutant 4Δ*vps4*Δ H1-Lro1 displayed a strong growth inhibition ([Figure 6](#fig6){ref-type="fig"}E). In contrast, 4Δ*vps4*Δ 3xMBP-LRO1 showed no defect, consistent with the notion that loss of viability is specifically linked to LD production at the INM. Since ESCRT-III is involved in membrane remodeling events in multiple organelles, we deleted *CHM7*, which is involved in the specific nuclear envelope recruitment of ESCRT-III ([@bib66], [@bib18]). Consistently, the double mutant 4Δ*chm7*Δ H1-Lro1 displayed a growth defect in the presence of oleate when compared to 4Δ H1-Lro1 ([Figure 6](#fig6){ref-type="fig"}F). 4Δ H1-Lro1 displayed also a growth defect when lacking *NUP188*, a component of the inner ring of the nuclear pore complex, further supporting the requirement of a functional nuclear envelope during INM-derived LD formation. Collectively, these data suggest that biosynthetic production of TG is likely to cause stress to the INM. By restricting PDAT activity to the nucleolar membrane, cells maintain nuclear integrity.

Discussion {#sec3}
==========

Eukaryotic cells possess efficient mechanisms for TG synthesis and packing at the cytoplasmic ER. Depending on the cellular metabolic requirements, fatty acids stored in TGs can be used for energy production and/or membrane biogenesis. In budding yeast, the tight association of the nucleolus with the nuclear periphery defines a membrane subdomain, which has been implicated in nuclear shape, nucleophagy, and rDNA anchoring to the nuclear envelope. We find that the yeast acyltransferase Lro1 is active at this subdomain, generating TGs from phospholipid-derived fatty acids, in response to cell cycle and nutrient signals.

Several reports have documented the presence of intranuclear LDs, but the origin of the TG composing them, as well as their roles, remain elusive ([@bib31], [@bib61], [@bib6], [@bib17], [@bib68], [@bib43], [@bib52]). The DGAT Dga1 makes the majority of TG in yeast cells at the stationary phase ([@bib40], [@bib54]). Under these conditions, we showed that Lro1 associates with, and concentrates at, the INM subdomain. Thus, our data support the notion of a restricted activity of Lro1 at the nuclear envelope, which may explain its limited contribution in bulk TG synthesis in wild-type cells during starvation ([@bib40]). Given its topology, however, we cannot exclude that Dga1 is also contributing to nuclear TG synthesis. In fact, DGAT2 association with intranuclear LDs was proposed to mediate their expansion in hepatocyte-derived cell lines ([@bib43]).

Although it is generally accepted that TG storage in LDs takes place at the ER, our data reveal that cells can survive during starvation when engineered to depend exclusively on TG generated at the INM. Given that the final destination of the TG-stored fatty acids during starvation are peroxisomes, mitochondria, and the vacuole, this result is consistent with the presence of a pathway that delivers nuclear TG to its cytoplasmic destinations. How such a process could operate will be the subject of future studies, but some scenarios can be hypothesized. Low levels of TG can be accommodated between the leaflets of a phospholipid bilayer and could diffuse through the nuclear pore membrane to the outer membrane, where they would be packed into mature LDs. Alternatively, budding of LDs toward the luminal side could channel them toward the outer nuclear membrane ([Figure 6](#fig6){ref-type="fig"}H). Our data on the requirement of nuclear membrane and pore integrity under conditions of enhanced TG synthesis at the INM is consistent with both scenarios. However, LDs can bud toward the nucleoplasm in mutants that affect the phospholipid composition of the ER and that of the LD monolayer, ([@bib6], [@bib17], [@bib52]). Therefore, membrane phospholipid composition may be critical in determining the directionality of LD budding.

In yeast cells, the nuclear membrane expands to allow anaphase to take place within an intact nucleus. The membrane associated with the nucleolus can also expand in response to excess phospholipid synthesis, resulting in alterations of nuclear shape ([@bib5], [@bib67]). Although the precise mechanisms of this process remain to be determined, one possibility could be that Lro1-mediated generation of either lysophospholipids or re-esterified phospholipids with a distinct fatty-acyl composition modifies the biophysical properties of this membrane subdomain and its dynamics. Because Lro1 targeting to this subdomain is prevented under conditions that require nuclear expansion, it is tempting to speculate that Lro1 plays a role in the regulation of this process. The pool of DG that is required for TG synthesis by Lro1 ([Figures 1](#fig1){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}D) could be provided by Pah1, which is known to target the nuclear envelope at the diauxic shift ([@bib2]), but other enzymes could act in concert with Lro1 as well. We cannot also exclude the possibility that Lro1 controls nuclear organization through additional mechanisms that are independent of its catalytic activity. The highly basic N-domain of Lro1 faces the nucleoplasm and its interaction with nucleic acid or protein components of the nucleolus could restrict the expansion of its membrane subdomain.

It is conceivable that Lro1-mediated membrane remodeling could also play additional roles at the INM. Changes in nuclear membrane dynamics may be required for the removal of nuclear material during starvation conditions via piecemeal microautophagy ([@bib51]) and receptor-mediated nucleophagy ([@bib37], [@bib38]). Both processes take place in proximity to the nucleolus. However, we found that at least one of these two processes, receptor-mediated nucleophagy, proceeds during glucose starvation in the absence of Lro1 (data not shown). Lro1-mediated membrane remodeling could be also linked to nucleolar functions. For example, rDNA transcription and ribosome biogenesis are energy-consuming processes acutely inhibited during starvation, and they lead to a decrease in nucleolar size ([@bib39]). Since the rDNA is physically tethered to the INM in yeast ([@bib35]) Lro1 could remodel this membrane subdomain to facilitate nucleolar reorganization during starvation. Future studies will be needed to fully elucidate the role of INM lipid composition in nucleolar functions.

Previous studies reported that PDATs are present in fungi, green algae and plants, and they have a topology similar to that of Lro1 ([@bib56], [@bib45]). Our analysis identified PDATs from two additional taxonomic groups, the flagellates Euglenozoa and the fungal-like Oomycetes ([Table S2](#mmc3){ref-type="supplementary-material"}). However, the nucleolar-associated membrane has been described so far only in fungi, raising the question of PDAT function in other taxonomic groups. Notably, the green algal *C. reinhardtii* PDAT was proposed to use chloroplast membrane lipids to synthesize TG during starvation ([@bib69]). Similarly, the *Arabidopsis thaliana* Lro1 ortholog PDAT1, which also generates TG using phospholipids as acyl donors ([@bib56]), re-localizes from the ER to chloroplasts following starvation induced by light deprivation (data not shown). Therefore, we speculate that PDATs respond to the need of remodeling or turnover of membranes. Given that the requirements of different cell types during stress are often distinct, PDATs may have evolved to target diverse organelles. It will be interesting to define the signals that govern PDAT dynamics in different cell types and examine whether animal cells, which lack apparent PDAT orthologs, maintain the ability to remodel membranes by a combination of phospholipase and acyltransferase activities.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit Polyclonal anti-GFPA. PedenN/AMouse monoclonal anti-HAAbcamCat\#Ab16918; RRID: [AB_302562](nif-antibody:AB_302562){#interref35}Goat polyclonal horseradish Peroxidase (HRP)-conjugated anti-rabbit Immunoglobulin-specificBD BiosciencesCat\#554021; RRID: [AB_395213](nif-antibody:AB_395213){#interref40}**Chemicals**RapamycinLC LaboratoriesCat\#R-5000BODIPY 493/503Thermo Fisher ScientificCat\#D-3922NocodazoleSigmaCat\#M1404Oleic acidSigmaCat\#05508-5ML-Fα1-Mating Factor acetate saltSigmaCat\#T6901CE\_(18:0~d6~)QMXCat\#D-5823Ceramide_C16~d31~AVANTICat\#868516PFA_C15:0~d29~QMXCat\#D-4020FA_C17:0~d33~QMXCat\#D-5261FA_C20:0~d39~QMXCat\#D-1617LPC\_(C14:0~d42~)QMXCat\#D-5885PA\_(C16:0~d31~ / C18:1)AVANTICat\#860453PPC\_(C16:0~d31~ / C18:1)AVANTICat\#860399PPE\_(C16:0~d31~ / C18:1)AVANTICat\#860374PPG\_(C16:0~d31~ / C18:1)AVANTICat\#860384PPI\_(C16:0~d31~ / C18:1)AVANTICat\#860042PPS\_(C16:0~d62~)AVANTICat\#860401PSM\_(C16:0~d31~)AVANTICat\#868584PTG\_(45:0~d29~)QMXCat\#D-5265TG\_(48:0~d31~)QMXCat\#D-5213TG\_(54:0~d35~)QMXCat\#D-5217**Experimental Models: Organisms/Strains***S. cerevisiae*: BY4741 *MATa his3*Δ*0 leu2*Δ*0 met15*Δ*0 ura3*Δ*0*Open BiosystemsBY4741*S. cerevisiae*: BY4742 *MATαhis3*Δ*1 leu2*Δ*0 lys2*Δ*0 ura3*Δ*0*Open BiosystemsBY4742*S. cerevisiae*: BY4741 *lro1*::*KanMX*This paperSS2543*S. cerevisiae*: BY4741 *lro1*::*KanMX NOP10-mCherry*::*HisMX6*This paperSS2754*S. cerevisiae*: BY4741 *lro1*::*KanMX hrd1*::*hphNT1*This paperSS2825*S. cerevisiae*: BY4741 *HIS3*::*pRS403-NOP1-RFP*This paperSS2907*S. cerevisiae*: BY4741 *ale1*::*KanMX*Open Biosystems*ale1ΔS. cerevisiae*: BY4741 *plb1*::*hphNT1 plb2*::*KanMX plb3*::*NatMX6 nte1*::*URA3 lro1*::*HIS3*This paperSS2410*S. cerevisiae*: BY4742 *asi3*::*KanMX*Open Biosystems*asi3ΔS. cerevisiae*: BY4742 *ctf19*::*KanMX*Open Biosystems*ctf19ΔS. cerevisiae*: BY4742 *mcm21*::*KanMX*Open Biosystems*mcm21ΔS. cerevisiae*: BY4741 *rad52*::*KanMX HIS3::pRS403-NOP1-RFP*This paperSS3031*S. cerevisiae*: BY4742 *vps4*::*KanMX*Open Biosystems*vps4ΔS. cerevisiae*: BY4741 *ALE1-GFP*::*hphNT1*This paperSS2874*S. cerevisiae*: BY4741 *LPL1-GFP*::*HIS3MX*[@bib22]*LPL1-GFPS. cerevisiae*: BY4741 *SLC1-GFP*::*HIS3MX*[@bib22]*SLC1-GFPS. cerevisiae*: *MATα his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 lys2*+*/lys*+ *can1Δ::STE2pr-sp HIS5 lyp1Δ::STE3pr-LEU2 LRO1-GFP-NatMX6*This paperSS2654*S. cerevisiae*: *MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 met15Δ0 are1::KanMX are2:KanMX trp1::URA lro1::TRP dga1::Lox-HIS-Lox*[@bib24]RSY3077 (a.k.a. 4Δ)*S. cerevisiae*: 4Δ *dgk1*::*HIS3MX6*[@bib2]SS2468*S. cerevisiae*: 4Δ *chm7*::*NatMX6*This paperSS2951*S. cerevisiae*: 4Δ *vps4*::*NatMX6*This paperSS2953*S. cerevisiae*: 4Δ *nup188*::*NatMX6*This paperSS2966*S. cerevisiae*: 4Δ *pom152*::*NatMX6*This paperSS2964*S. cerevisiae*: 4Δ *FAA4-GFP-HISMX6*This paperSS2922*S. cerevisiae*: W303 *MATα tor1-1 fpr1*::*NAT*EUROSCARFK14708*S. cerevisiae*: W303 *MATα tor1-1 fpr1*::*NAT HEH1-2xFKBP12*::*TRP1 lro1*::*KanMX*This paperSS2745*S. cerevisiae*: W303 *MATα tor1-1 fpr1::NAT HEH1-2xFKBP12::TRP1 lro1::KanMX dga1::hphNT1*This paperSS2991*S. cerevisiae*: W303 *MATα tor1-1 fpr1::NAT HEH1-2xFKBP12::TRP1 lro1::KanMX dgk1*::*HIS3*This paperSS3037*S. cerevisiae*: W303 *MATα tor1-1 fpr1*::*NAT RPL13A-2×FKBP12*::*TRP1*EUROSCARFHHY168*S. cerevisiae*: W303 *MATα tor1-1 fpr1*::*NAT RPL13A-2×FKBP12*::*TRP1 RPA135-FRB*::*KanMX*This paperSS2837**Recombinant DNA***LRO1* under control of *LRO1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*LRO1LRO1-GFP* under control of *LRO1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*LRO1-GFPLRO1-mCherry* under control of *LRO1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*LRO1-mCherryLRO1-6xHA* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*LRO1-6xHALRO1-GFP* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*LRO1-GFP4xIgGb-LRO1Δ\[2-77\]-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*4xIgGb*-*LRO1-GFP1xMBP-LRO1-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*1xMBP*-*LRO1-GFP2xMBP-LRO1-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*2xMBP*-*LRO1-GFP3xMBP-LRO1-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*3xMBP*-*LRO1-GFPLRO1\[1-79\]-GFP* under control of *LRO1* promoter in *CEN/URA3* vectorThis paperYCplac33-*LRO1\[1-79\]-GFPLRO1\[1-103\]-GFP* under control of *LRO1* promoter in *CEN/URA3* vectorThis paperYCplac33-*LRO1\[1-103\]-GFPLRO1\[44-AAAA-47; 71-AAAWA-75\]-GFP* under control of *LRO1* promoter in *CEN/URA3* vectorThis paperYCplac33-*LRO1-NLS-GFPLRO1\[1-79; 44-AAAA-47; 71-AAAWA-75\]-GFP* under control of *LRO1* promoter in *CEN/URA3* vectorThis paperYCplac33-*LRO1\[1-79\]-NLS-GFPLRO1\[1-103; 44-AAAA-47; 71-AAAWA-75\]-GFP* under control of *LRO1* promoter in *CEN/URA3* vectorThis paperYCplac33-*LRO1\[1-103\]-NLS-GFPFRB-LRO1-GFP* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*FRB*-*LRO1-GFPFRB-LRO1\[S324A\]-GFP* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*FRB*-*LRO1-S324A-GFPFRB-GFP* under control of *NOP1* promoter in *CEN*/*LEU2* vectorThis paperYCplac111-*NOP1*pr-*FRB*-*GFPFRB*-*3xMBP*-*LRO1-GFP* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr- *FRB*-*3xMBP*-*LRO1-GFPLRO1\[S324A\]-GFP* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*LRO1-S324A-GFPLRO1* under control of *NOP1* promoter in *CEN*/*URA3* vectorThis paperYCplac33-*NOP1*pr-*LRO1HEH1\[163-454\]-LRO1Δ\[2-77\]* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*H1*-*LRO1HEH1\[163-454\]-LRO1Δ\[2-77\]-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*H1*-*LRO1-GFPHEH1\[163-225\]-LRO1Δ\[2-77\]* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*H1Δ\[UP\]*-*LRO1HEH1\[163-225\]-LRO1Δ\[2-77\]-GFP* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*H1Δ\[UP\]*-*LRO1-GFP3xMBP-LRO1* under control of *NOP1* promoter in *CEN/URA3* vectorThis paperYCplac33-*NOP1*pr-*3xMBP-LRO1LRO1* under control of *GAL1*/*10* promoter in *2μ/LEU2* vectorThis paperYEplac181 *GAL1*/*10-LRO1LRO1\[S324A\]* under control of *GAL1*/*10* promoter in *2μ/LEU2* vectorThis paperYEplac181 *GAL1*/*10-LRO1-S324APAH1-7A* under control of *GAL1*/*10* promoter in *2μ/LEU2* vector[@bib42]YEplac181-*GAL1/10-PAH1-7ANTE1-GFP* under control of *NTE1* promoter in *CEN*/*LEU2* vectorThis paperYCplac111-*NTE1-GFPSEC63-mCherry* under control of *SEC63* promoter in *CEN*/*LEU2* vectorThis paperYCplac111-*SEC63-mCherryPUS1-GFP* under control of *PUS1* promoter in *CEN*/*LEU2* vectorThis paperYCplac111-*PUS1-GFPNOP1-RFP* under control of *NOP1* promoter in *CEN*/*TRP1* vectorThis paperpRS314-*NOP1-RFPNOP1-RFP* under control of *NOP1* promoter in *CEN*/*HIS3* vectorThis paperpRS313-*NOP1-RFPNUP84-mCherry* under control of *NUP84* promoter in *CEN*/*LEU2* vector[@bib2]YCplac111-*NUP84-mCherry*

Lead Contact and Materials Availability {#sec5.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Symeon Siniossoglou (<ss560@cam.ac.uk>).

Experimental Models and Subject Details {#sec5.3}
---------------------------------------

### Yeast Strains, Plasmids, Media and Growth Conditions {#sec5.3.1}

Unless otherwise specified, reagents were obtained from Sigma (St. Louis, MO). Yeast strains and plasmids are described in the [Key Resources Table](#sec5.1){ref-type="sec"}. Yeast plasmids were generated using standard PCR and cloning techniques. Cells were transformed using the lithium acetate method. Gene deletions and epitope tagging by chromosomal integration were generated by one-step polymerase chain reaction (PCR)-based method ([@bib32], [@bib26], [@bib19]) and confirmed by PCR. In most experiments, cells were grown overnight at 30°C in synthetic complete (SC) medium containing 2% glucose, 0.2% yeast nitrogen base (YNB, Difco, BD, Franklin Lakes, NJ), 0.6% ammonium sulfate and amino acids drop-out (60 mg/L leucine, 55 mg/L adenine, 55 mg/L uracil, 55 mg/L tyrosine, 20 mg/L of arginine, 10 mg/L histidine, 60 mg/L isoleucine, 40 mg/L lysine, 60 mg/L phenylalanine, 50 mg/L threronine, 10 mg/L methionine, 40 mg/L tryptophan) to exponential phase (to OD~600nm~ 0.4-0.6), PDS phase (inoculated at OD~600nm~ 0.05 and grown for approximately 15h to OD~600nm~ 4-6), or the indicated OD~600nm~, from fresh pre-cultures, according to the previously determined growth rate in this medium ([@bib2]). For stationary phase survival assays, cells were grown in minimal medium (MM) with 0.17% yeast nitrogen base (Difco, BD, Franklin Lakes, NJ), 0.5% ammonium sulfate and amino acids drop-out (20 mg/L uracil, 20 mg/L histidine, 20 mg/L methionine, 30 mg/L leucine, and 30 mg/L lysine) to PDS phase (OD~600nm~ ∼ 4), and viability was measured every 24 hours by standard dilutions on YEP plates \[2% glucose, 2% bactopeptone (BD, Franklin Lakes, NJ), 1% yeast extract (BD, Franklin Lakes, NJ)\] with 2% glucose (YEPD medium) and 2% agar (Biogene, Kimbolton, UK). When required, SC and MM media lacked the appropriate amino acids for plasmid selection.

For *GAL1/10* promoter-mediated overexpression, cells were first pre-grown in selective SC medium with 2% glucose, grown overnight in selective SC medium with 2% raffinose, and transferred to selective SC medium with 2% galactose for the indicated times.

LD biogenesis in the presence of glucose was induced by growing the cells in YEPD with 1 mM oleic acid and 1% tergitol (solid media), or 0.1% oleic acid (3.2 mM oleate) and 0.2% Tween-80 pH 6.0 (in liquid media). Oleic acid uptake was confirmed by growth inhibition of the 4Δ strain ([@bib46]).

Growth assays on plates were performed using cells at the growth phase and media indicated in the figure legends. Serial dilutions were spotted onto the appropriate plates and incubated at 30°C for 2--4 days.

Method Details {#sec5.4}
--------------

### Fluorescence Microscopy {#sec5.4.1}

Lro1-GFP localization under stress conditions was tested transferring exponential cells for 1 h or 2 h into SC medium lacking a carbon source (carbon starvation), nitrogen starvation medium (2% glucose, 0.17% YNB), SC medium with 2% glycerol as carbon source (respiratory growth), or H~2~O. An overnight culture grown to PDS phase was used as control, and targeting to the nucleolus was expressed as percentage of targeting in PDS. Enrichment of Lro1-GFP at the nucleolus in exponential phase was determined in asynchronous cultures. Rapamycin-induced heterodimerization of FKBP12 with the FRB domain of human mTOR was performed as previously described in the anchor-away technique ([@bib19]). Briefly, cells were grown in selective SC medium to exponential phase and treated with 1 μg/ml rapamycin for 30 min. In nocodazole-mediated cell cycle arrest experiments, *GAL1/10* promoter-mediated overexpression was induced as described above but growing the cells in YEP media with 2% galactose for 3 h before adding 15 μg/mL nocodazole for 2 h; in the anchor-away strains, cells were first transferred to YEPD media and treated with 1 μg/ml rapamycin for 30 min before adding 15 μg/mL nocodazole for 2 h. For alpha-factor cell cycle arrest, cells were treated with 10 μM alpha-factor for 2 h in YEPD. Lipid droplets were stained with 1.25 μg/ml BODIPY 493/503 for 10 min at room temperature.

Cells grown to the indicated growth phases were pelleted and immediately imaged live at room temperature in a Zeiss AxioImager.Z2 epifluorescence upright microscope with a 100× Plan-Apochromatic 1.4 numerical aperture (NA) objective lens (Carl Zeiss Ltd, Jena, Germany). Images were recorded using a large chip sCMOS mono camera for sensitive fluorescence imaging (ORCA Flash 4.0v2, Hamamatsu, Hamamatsu, Japan), saved by Zeiss ZEN2.3 software (Blue edition, Carl Zeiss Ltd, Jena, Germany) and exported to Adobe Photoshop (Adobe, San Jose, CA). Where indicated, cells were mounted on a 1% agarose pad and imaged using a Zeiss LSM880 confocal microscope with Airyscan and the ZEN2 software (Carl Zeiss Ltd, Jena, Germany). Cells were visualized from the periphery by taking 0.2 μm step slices and 50% overlap, and 0.187 μm axial resolution. All microscopy images were captured blindly and quantifications were performed on fields obtained from independent experiments.

For three-dimensional (3D) analysis, through-focus image series were deconvolved with Volocity 6.3 (PerkinElmer, Waltham, MA) using calculated point-spread functions and 3D iterative restoration processing to form 3D image stacks. Stacks were then visualized using Volocity 6.3 (PerkinElmer, Waltham, MA) to generate the 3D images or movies showing the organelles at different positions. For circularity and surface of the nucleus measurements, through-focus image series were deconvolved with Volocity 6.3 (PerkinElmer, Waltham, MA) and merged in 2D images showing the brightest intensity through z, which were exported and analysed in ImageJ 1.47v (NIH, Bethesda, MD).

Time-lapse imaging was performed in a Leica TCS SP8 confocal microscope. Yeast cells (4Δ) expressing Faa4-GFP, Nop1-RFP, and Lro1 under its endogenous promoter in a *CEN* vector, were grown in selective media to PDS phase and imaged on 2% agar pads. Images were acquired using a 63x oil immersion objective lens with an 8x zoom factor at 30 seconds intervals using white light laser at 488nm and 578nm for the excitation of GFP and RFP, respectively. Videos were generated using Imaris at a rate of three frames/second.

### Fluorescence Recovery after Photobleaching {#sec5.4.2}

Photobleaching experiments were performed on a Leica TCS SP8 confocal microscope with the optional FRAP Booster enabled. Yeast *lro1Δ* cells expressing LRO1-GFP from *NOP1* promoter were pelleted and imaged at room temperature at early PDS phase. Images were acquired using a 63x oil immersion objective lens. After acquiring two images at 5-sec intervals, selected regions of interest were photobleached with 3 iterations of 100% laser power (white light laser) at 488 nm. The fluorescence intensity of GFP at the regions of interest was recorded for another 13 frames at 20 sec intervals. For data analyses, the fluorescence intensity of GFP was corrected by the percentage loss of GFP fluorescence intensity obtained from cells under identical conditions but without a photobleaching event. To calculate halftime of recovery (T~1/2~), exponential FRAP curve fitting (non-linear regression, one way association) was obtained using GraphPad Prism after excluding the two pre-bleaching measurement points. Mobile fraction of LRO1-GFP was calculated by subtracting the % of fluorescence intensity at T0 (I0) from the plateau level (Ie); while, immobile fraction was calculated by subtracting the mobile fraction from 100%.

### Automated Yeast Library Manipulations and High-Throughput Microscopy Screen {#sec5.4.3}

Lro1-GFP, expressed from the *NOP1* promoter in a CEN/ARS *URA3* vector, was introduced in the KanMX deletion and DAmP collections ([@bib14], [@bib4]) by Synthetic Genetic Array, by standard procedures previously described ([@bib8]), using the RoToR bench-top colony arrayer (Singer Instruments, Roadwater, Watchet, UK). Cells were imaged, at room temperature at PDS phase in SC medium lacking uracil, using the automated inverted fluorescent microscopic ScanR system (Olympus, Waltham, Massachusetts, USA), with a 60× air lens, for GFP (excitation, 490/20 nm; emission, 535/50 nm) and brightfield channels. After acquisition, images were manually reviewed using the ImageJ software (NIH, Bethesda, MD). Cells showing increased Lro1-GFP signal in the ER, or overall decreased targeting to the nucleolus without enrichment at other subcellular localizations were selected for further analysis. The data obtained were analysed with GO (gene ontology) term finder of Saccharomyces Genome Database to determine GO term enrichment (<https://www.yeastgenome.org/goTermFinder>), and selecting the "Process" ontology aspect. Based on this analysis, Lro1-GFP localization was then manually inspected in mutants of interest (see [Table S1](#mmc2){ref-type="supplementary-material"}).

### Electron Microscopy {#sec5.4.4}

Cells were grown to the indicated growth phases, chemically fixed, embedded in 12% gelatin and cryo-sectioned as described previously ([@bib16]). Ultrathin cryo-sections were collected with a 1:1 mixture of 2% methylcellulose and 2.3 M, sucrose 120 mM PIPES, 50 mM HEPES, pH 6.9, 4 mM MgCl~2~, 20 mM EGTA, and layered on Formvar/carbon coated 100 mesh copper grids. Immunological reactions were performed using a polyclonal anti-HA and a protein A-gold 10 nm conjugate (Cell Microscopy Center, Utrecht, The Netherlands). To determine protein localization, the distribution of gold particles was counted in 100 cells. The relative distribution of Lro1-6xHA to the cortical and the nuclear ER, was performed by counting the number of gold particles associated to these two cellular sub-compartments, on cell profiles randomly screened from immuno-labeled cell sections derived from at least three different grids. Gold particles were assigned to a compartment when no further than 10 nm away from its limiting membrane.

For high-pressure freezing electron microscopy, 4Δ H1-Lro1 cells were grown to PDS phase, pelleted and resuspended in a minimum volume of 20% BSA + 5% FBS/PBS to form a paste, and this paste was pipetted into flat specimen carriers and high-pressure frozen with a Leica EM PACT2. Freeze-substitution was performed with a Leica EM AFS2, and pellets were immersed in 0.1% tannic acid/acetone at -90°C for 24 hours, before being replaced by 2% osmium/ 0.1% UA (methanolic)/acetone for 48 hours at -90°C. Samples were then gradually warmed as follows; warmed to -56°C at a rate of 5°C/hour, held at -56°C for 12 hours, warmed to -20°C at a rate of 5°C/hour, held at -20°C for 12 hours, warmed to +4°C at a rate of 5°C/hour, held at +4°C for 4 hours. Pellets were washed three times with acetone before being gradually infiltrated with Spurr's resin over a period of 4 days. Ultrathin sections were cut using a diamond knife mounted to a Reichert Ultracut S ultramicrotome, and floating sections were collected onto copper grids. Grids were poststained first with both 2% uranyl acetate/70% methanol for 4 minutes and then with lead citrate for 4 minutes. Sections were viewed on an FEI Tecnai transmission electron microscope at a working voltage of 80 kV.

### Yeast Lipid Profiling {#sec5.4.5}

Yeast cells were prepared for mass spectrometry analysis as previously described ([@bib12]) with minor modifications. Briefly, 50 mg of yeast cells were re-suspended in 1 mL of 2:1 chloroform-methanol mixture (v/v), with the addition of 150 μL of the following internal standard solution (approximately 10 to 50 μM in methanol): CE\_(18:0~d6~), Ceramide_C16~d31~, FA_C15:0~d29~, FA_C17:0~d33~, FA_C20:0~d39~, LPC\_(C14:0~d42~), PA\_(C16:0~d31~ / C18:1), PC\_(C16:0~d31~ / C18:1), PE\_(C16:0~d31~ / C18:1), PG\_(C16:0~d31~ / C18:1), PI\_(C16:0~d31~ / C18:1), PS\_(C16:0~d62~), SM\_(C16:0~d31~), TG\_(45:0~d29~), TG\_(48:0~d31~), and TG\_(54:0~d35~). The cells were homogenized with 100 mg 0.5 mm diameter glass beads (BioSpec Products, Bartlesville Oklahoma, USA) in a FastPrep-24 instrument (MP Biomedicals, Santa Ana California, USA), using five short pulses at 5 m/s for 1 min; with one minute on ice between each pulse to prevent over-heating. Then 400 μL of sterile water was added to the homogenates, vortexed for 1 min, and then centrifuged at 13,200 rpm for 10 minutes. The organic layer was collected in a 2 mL amber glass vial (Agilent Technologies, Santa Clara California, USA) and the remaining mixture was then treated with a second lipid extraction following the same procedure. The two organic layers were combined and air-dried overnight in a fume hood.

For lipid analysis, we used a method previously described with minor modification ([@bib29], [@bib33]). Full chromatographic separation of intact lipids was achieved using Shimadzu HPLC System (Shimadzu UK Limited, Milton Keynes, United Kingdom) with the injection of 10 μL onto an Acquity UPLC® CSH C18 column; 1.7 μm, I.D. 2.1 mm X 50 mm, maintained at 55°C. Mobile phase A was 6:4, acetonitrile and water with 10 mM ammonium formate. Mobile phase B was 9:1, 2-propanol and acetonitrile with 10 mM ammonium formate. The flow was maintained at 500 μL per minute through the following gradient: 0.00 minutes_40% mobile phase B; 0.40 minutes_43% mobile phase B; 0.45 minutes_50% mobile phase B; 2.40 minutes_54% mobile phase B; 2.45 minutes_70% mobile phase B; 7.00 minutes_99% mobile phase B; 8.00 minutes_99% mobile phase B; 8.3 minutes_40% mobile phase B; 10 minutes_40% mobile phase B. The sample injection needle was washed using 9:1, 2-propanol and acetonitrile with 0.1 % formic acid.

The mass spectrometer used was the Thermo Scientific Exactive Orbitrap with a heated electrospray ionisation source (Thermo Fisher Scientific, Hemel Hempstead, UK). The mass spectrometer was calibrated immediately before sample analysis using positive and negative ionisation calibration solution (recommended by Thermo Scientific). Additionally, the heated electrospray ionisation source was optimised at 50:50 mobile phase A to mobile phase B for spray stability (capillary temperature; 380°C, source heater temperature; 420°C, sheath gas flow; 60 (arbitrary), auxiliary gas flow; 20 (arbitrary), sweep gas; 5 (arbitrary), source voltage; 3.5 kV. The mass spectrometer resolution was set to 25,000 with a full-scan range of m/z 150 to 1200 Da, with continuous switching between positive and negative mode.

Lipid quantification was achieved using the area under the curve (AUC) of the corresponding high resolution extracted ion chromatogram (with a window of ± 8 ppm) at the indicative retention time. The lipid analyte AUC relative to the internal standard AUC for that lipid class was used to semi-quantify and correct for any extraction/instrument variation. The normalized analyte intensities (analyte to internal standard ratios) were then expressed as a percentage of the total lipids extracted from that sample (mol %).

### Immunoblotting {#sec5.4.6}

Yeast cells (approximately 12 OD~600~) were pelleted, washed with sterile water, and lysed in 100 μl SDS-sample buffer with 0.5 mm diameter glass beads (BioSpec Products, Bartlesville, OK) by two rounds of boiling for 2 min and vortexing for 30 sec. Protein extracts were centrifuged at 13,000 rpm for 15 min, and the supernatants analysed by Western blot. Western blot signals were developed using ECL (GE Healthcare, Little Chalfont UK).

### Flow Cytometry {#sec5.4.7}

Quantification of BODIPY by flow cytometry was performed as previously described ([@bib2]). Briefly, cells were fixed for 30 min at room temperature with 3.7% formaldehyde, washed once with phosphate-buffered saline, and incubated with 10 μM BODIPY 493/503 for 10 min at room temperature. Labelling was immediately measured using the FL-1 detector of a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA), and the results analysed with FlowJo software, version 9 (Tree Star, Ashland, OR).

### Bioinformatics {#sec5.4.8}

For the identification of PDATs, the UniProt Knowledgebase (UniProtKB) was searched with the search term phospholipid:diacylglycerol acyltransferase at <http://www.uniprot.org/>. Partial sequences, sequences with zero or multiple transmembrane domains were removed. In order to extend the number of PDATs, we performed a phmmer search on the HMMER web server at <https://www.ebi.ac.uk/Tools/hmmer/> ([@bib11]) using the *S. cerevisiae* Lro1 (UniProtKB accession P40345) sequence to query UniProtKB. Additional plant PDATs, identified in [@bib45] were obtained from the Phytozome resource ([@bib15]).

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

Unless otherwise stated, data were obtained from at least three independent repeats. The micrographs presented are representative of the results obtained. Signal intensity, surface and circularity were measured using ImageJ 1.47v (NIH, Bethesda, MD). Results were expressed as mean ± standard deviation. Data were analysed with unpaired, two-tailed t tests or one-way ANOVA with Tukey\'s multiple comparison test when more than two groups were compared using GraphPad Prism 5 software (GraphPad, La Jolla, CA). Statistical significance was defined as: ^∗^, p \< 0.05; ^∗∗^, p \< 0.01; and ^∗∗∗^, p \< 0.001.

Data and Code Availability {#sec5.6}
--------------------------

Datasets associated with this study are provided in [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}.
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